Long-term survival after ischemic stroke in patients with atrial fibrillation

Neurology

Volumn 82, Issue 12, 2014, Pages 1033-1037

  Fang, Margaret C ^a   Go, Alan S ^a,b   Chang, Yuchiao ^c   Borowsky, Leila H ^c   Pomernacki, Niela K ^b   Udaltsova, Natalia ^b   Singer, Daniel E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIVISION OF RESEARCH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RISK; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84898718521     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000248     Document Type: Article

References (26)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-1564.
4. Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States. Stroke 2011;42: 2351-2355.
5. Slot KB, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 2008;336:376-379.
6. Eriksson M, Norrving B, Terént A, Stegmayr B. Functional outcome 3 months after stroke predicts long-term survival. Cerebrovasc Dis 2008;25:423-429.
7. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 1996;27: 1760-1764.
8. Lopes RD, Shah BR, Olson DM, et al. Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL registry. Stroke 2011;42:3477-3483.
9. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point. Circ Cardiovasc Qual Outcomes 2011;4:14-21.
10. Casciano JP, Singer DE, Kwong WJ, Fox ES, Martin BC. Anticoagulation therapy for patients with non-valvular atrial fibrillation. Am J Cardiovasc Drugs 2012;12:313-323.
11. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. Ann Intern Med 1999;131:927-934.
12. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-2692.
13. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-1402.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
15. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054.
16. Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 2012;43:1795-1799.
17. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (the European Community Stroke Project). Stroke 2001;32:392-398.
18. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after firstever stroke: the Oxfordshire Community Stroke Project. Stroke 1993;24:796-800.
19. Boysen G, Marott JL, Grønbæk M, Hassanpour H, Truelsen T. Long-term survival after stroke: 30 years of follow-up in a cohort, the Copenhagen City Heart Study. Neuroepidemiology 2009;33:254-260.
20. Hartmann A, Rundek T, Mast H, et al.Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study. Neurology 2001;57:2000-2005.
21. Vernino S, Brown RD Jr, Sejvar JJ, Sicks JD, Petty GW, O'Fallon WM. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke 2003; 34:1828-1832.
22. Rutten-Jacobs LA, Arntz RM, Maaijwee NM, et al. Longterm mortality after stroke among adults aged 18 to 50 years. JAMA 2013;309:1136-1144.
23. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-810.e2.
24. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF Study. Am Heart J 2010;159:340-347.e1.
25. Hart R, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
26. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026.